Category Archives: MS Treatment

NEW YORK, Sept. 28, 2020 /PRNewswire/ -- Immunic, Inc. Continue reading →

Emerging data is showing that treatment within 6 months of presentation of multiple sclerosis (MS) is ideal, explained Patricia K. Continue reading →

A new study suggeststhe need for caution in switching from fingolimod to a B celldepleting anti-CD20 treatment such as ocrelizumab for patients with multiple sclerosis (MS). Italian researchers report an increased risk for prolonged reductions in T-cell counts, in addition to depletion of B cells, among patients who make this switch. Such depletion could increase the risk for infection, a particular concern in the current COVID era Continue reading →

Defending its blockbuster multiple sclerosis drug Tecfidera from generics hasn't been easy for Biogen lately, and the painful trend continuedthis week with a court ruling thatclears the way for more copycat drugs to launch. After the Delaware patent court loss this week, multiple generics will likely roll out soon, Bernstein analyst Ronny Galpredictsand when they do, they'll siphon off most of Tecfidera's $3 billion-plus in U.S. Continue reading →

The following article is part of conference coverage from the 8th Joint American Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) and European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) MSVirtual2020 event. Neurology Advisors staff will be reporting breaking news associated with research conducted by leading experts in neurology. Continue reading →

Marthas Vineyard Hospital leaders urged Vineyarders to not postpone care and to schedule flu shots as the fall begins, breathing a sigh of relief about the summer but preparing for the unknown months that lie ahead for homelessness and drug use prevention. During the hospitals biweekly press briefing Wednesday morning, president and chief executive officer Denise Schepici said there is evidence that patients are postponing care and arriving at the hospital with acute illnesses that require treatment off-Island. Continue reading →

Garner Insights has added a new report titled, Global Primary Progressive Multiple Sclerosis Treatment Market Professional Report 2026 to its vast repository of research reports. This is a thorough report focused on the current and future prospects of the Global Primary Progressive Multiple Sclerosis Treatment Market. The report offers data of previous years along with an in-depth analysis from 2020 to 2026 on the basis of revenue (USD Billion) Continue reading →

Cyclists participating in Bike MS 2019 ride. // Photo by Kent Ruby Photography The woman with progressive multiple sclerosis who struggles to button her shirt in the morning, yet is determined to stand up and dance at her granddaughters wedding Continue reading →

NEWTON, Mass.--(BUSINESS WIRE)--Inflammasome Therapeutics (http://www.inflam.com), a privately held company developing therapies for prevalent, degenerative diseases, reported that data analyses published today in Nature Communications https://www.nature.com/articles/s41467-020-18528-z showed that patients taking nucleoside reverse transcriptase inhibitors (NRTIs), drugs used to treat HIV for more than 30 years, reduced their risk of developing type 2 diabetes by 33%, a highly statistically significant result (p < 0.0001). Nineteen coauthors from leading institutions examined data from 128,861 patients over 17 years from five large national health insurance databases to assess the relationship between treatment with NRTIs and development of type 2 diabetes. The study also found that lamivudine, a commonly used NRTI, inhibited inflammasome activation, implicated as a key driver of type 2 diabetes, restored insulin sensitivity in type 2 diabetic human cells and prevented development of insulin resistance in non-diabetic human cells Continue reading →

Michael Costanzo, a Colorado farmer diagnosed with multiple sclerosis in 2016, has a well-honed ritual: Every six months, he takes an IV infusion of a medicine, Rituxan, to manage his disease, which has no cure. Then he figures out how to manage the bill, which costs thousands of dollars Continue reading →